BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 25143484)

  • 21. The direct Myc target Pim3 cooperates with other Pim kinases in supporting viability of Myc-induced B-cell lymphomas.
    Forshell LP; Li Y; Forshell TZ; Rudelius M; Nilsson L; Keller U; Nilsson J
    Oncotarget; 2011 Jun; 2(6):448-60. PubMed ID: 21646687
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The IKK2/NF-{kappa}B pathway suppresses MYC-induced lymphomagenesis.
    Klapproth K; Sander S; Marinkovic D; Baumann B; Wirth T
    Blood; 2009 Sep; 114(12):2448-58. PubMed ID: 19628709
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A transgenic mouse model demonstrating the oncogenic role of mutations in the polycomb-group gene EZH2 in lymphomagenesis.
    Berg T; Thoene S; Yap D; Wee T; Schoeler N; Rosten P; Lim E; Bilenky M; Mungall AJ; Oellerich T; Lee S; Lai CK; Umlandt P; Salmi A; Chang H; Yue L; Lai D; Cheng SW; Morin RD; Hirst M; Serve H; Marra MA; Morin GB; Gascoyne RD; Aparicio SA; Humphries RK
    Blood; 2014 Jun; 123(25):3914-24. PubMed ID: 24802772
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MYC-driven malignant transformation of mature murine B cells requires inhibition of both intrinsic apoptosis and p53 activity.
    Högstrand K; Grandien A
    Eur J Immunol; 2019 Mar; 49(3):375-385. PubMed ID: 30281155
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ERK-dependent downregulation of Skp2 reduces Myc activity with HGF, leading to inhibition of cell proliferation through a decrease in Id1 expression.
    Li X; Bian Y; Takizawa Y; Hashimoto T; Ikoma T; Tanaka J; Kitamura N; Inagaki Y; Komada M; Tanaka T
    Mol Cancer Res; 2013 Nov; 11(11):1437-47. PubMed ID: 24177224
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MYC selects against reduced BCL2A1/A1 protein expression during B cell lymphomagenesis.
    Sochalska M; Schuler F; Weiss JG; Prchal-Murphy M; Sexl V; Villunger A
    Oncogene; 2017 Apr; 36(15):2066-2073. PubMed ID: 27694901
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bptf determines oncogenic addiction in aggressive B-cell lymphomas.
    Richart L; Felipe I; Delgado P; Andrés MP; Prieto J; Pozo ND; García JF; Piris MA; Ramiro A; Real FX
    Oncogene; 2020 Jun; 39(25):4884-4895. PubMed ID: 32451433
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Selective transcriptional regulation by Myc in cellular growth control and lymphomagenesis.
    Sabò A; Kress TR; Pelizzola M; de Pretis S; Gorski MM; Tesi A; Morelli MJ; Bora P; Doni M; Verrecchia A; Tonelli C; Fagà G; Bianchi V; Ronchi A; Low D; Müller H; Guccione E; Campaner S; Amati B
    Nature; 2014 Jul; 511(7510):488-492. PubMed ID: 25043028
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting ornithine decarboxylase in Myc-induced lymphomagenesis prevents tumor formation.
    Nilsson JA; Keller UB; Baudino TA; Yang C; Norton S; Old JA; Nilsson LM; Neale G; Kramer DL; Porter CW; Cleveland JL
    Cancer Cell; 2005 May; 7(5):433-44. PubMed ID: 15894264
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Myc-mediated proliferation and lymphomagenesis, but not apoptosis, are compromised by E2f1 loss.
    Baudino TA; Maclean KH; Brennan J; Parganas E; Yang C; Aslanian A; Lees JA; Sherr CJ; Roussel MF; Cleveland JL
    Mol Cell; 2003 Apr; 11(4):905-14. PubMed ID: 12718877
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pim1 promotes human prostate cancer cell tumorigenicity and c-MYC transcriptional activity.
    Kim J; Roh M; Abdulkadir SA
    BMC Cancer; 2010 Jun; 10():248. PubMed ID: 20515470
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The epigenetic modifier JMJD6 is amplified in mammary tumors and cooperates with c-Myc to enhance cellular transformation, tumor progression, and metastasis.
    Aprelikova O; Chen K; El Touny LH; Brignatz-Guittard C; Han J; Qiu T; Yang HH; Lee MP; Zhu M; Green JE
    Clin Epigenetics; 2016; 8():38. PubMed ID: 27081402
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SKP2 oncogene is a direct MYC target gene and MYC down-regulates p27(KIP1) through SKP2 in human leukemia cells.
    Bretones G; Acosta JC; Caraballo JM; Ferrándiz N; Gómez-Casares MT; Albajar M; Blanco R; Ruiz P; Hung WC; Albero MP; Perez-Roger I; León J
    J Biol Chem; 2011 Mar; 286(11):9815-25. PubMed ID: 21245140
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Disruption of the Myc-PDE4B regulatory circuitry impairs B-cell lymphoma survival.
    Nam J; Kim DU; Kim E; Kwak B; Ko MJ; Oh AY; Park BJ; Kim YW; Kim A; Sun H; Jung Y; Lee JH; Shin HJ; Park I; Song DK; Jeong JY; Lee YH; Kim SW
    Leukemia; 2019 Dec; 33(12):2912-2923. PubMed ID: 31138843
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Small-molecule SUMO inhibition for biomarker-informed B-cell lymphoma therapy.
    Demel UM; Wirth M; Yousefian S; Zhang L; Isaakidis K; Dönig J; Böger M; Singh N; Köse H; Haas S; Müller S; Schick M; Keller U
    Haematologica; 2023 Feb; 108(2):555-567. PubMed ID: 36134453
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SUMO pathway inhibition targets an aggressive pancreatic cancer subtype.
    Biederstädt A; Hassan Z; Schneeweis C; Schick M; Schneider L; Muckenhuber A; Hong Y; Siegers G; Nilsson L; Wirth M; Dantes Z; Steiger K; Schunck K; Langston S; Lenhof HP; Coluccio A; Orben F; Slawska J; Scherger A; Saur D; Müller S; Rad R; Weichert W; Nilsson J; Reichert M; Schneider G; Keller U
    Gut; 2020 Aug; 69(8):1472-1482. PubMed ID: 32001555
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impaired ribosome biogenesis checkpoint activation induces p53-dependent MCL-1 degradation and MYC-driven lymphoma death.
    Domostegui A; Peddigari S; Mercer CA; Iannizzotto F; Rodriguez ML; Garcia-Cajide M; Amador V; Diepstraten ST; Kelly GL; Salazar R; Kozma SC; Kusnadi EP; Kang J; Gentilella A; Pearson RB; Thomas G; Pelletier J
    Blood; 2021 Jun; 137(24):3351-3364. PubMed ID: 33512431
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular and cytological features of the mouse B-cell lymphoma line iMycEmu-1.
    Han SS; Shaffer AL; Peng L; Chung ST; Lim JH; Maeng S; Kim JS; McNeil N; Ried T; Staudt LM; Janz S
    Mol Cancer; 2005 Nov; 4():40. PubMed ID: 16277667
    [TBL] [Abstract][Full Text] [Related]  

  • 39. JNK1 and JNK2 play redundant functions in Myc-induced B cell lymphoma formation.
    Anbalagan M; Sabapathy K
    Int J Cancer; 2012 Apr; 130(8):1967-9. PubMed ID: 21630260
    [No Abstract]   [Full Text] [Related]  

  • 40. Induction of ectopic Myc target gene JAG2 augments hypoxic growth and tumorigenesis in a human B-cell model.
    Yustein JT; Liu YC; Gao P; Jie C; Le A; Vuica-Ross M; Chng WJ; Eberhart CG; Bergsagel PL; Dang CV
    Proc Natl Acad Sci U S A; 2010 Feb; 107(8):3534-9. PubMed ID: 20133585
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.